CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches

Table 1

Properties of selected diagnostic and therapeutic radionuclides. Some low abundance emissions have been omitted for clarity. β+: positron emission, γ: gamma ray emission, PET: positron emission tomography, and SPECT: single-photon emission computed tomography.

Radionuclide	Half-life	Decay mode	Energy (keV)	Max range in tissue	Major application
^18F	1.83 h	β+ (97%)	633		PET
^11C	20.4 min	β+ (99.8%)	960		PET
^68Ga	1.1 h	β+ (88%)	1899		PET
^89Zr	3.3 d	β+ (23%)	897		PET
^64Cu	12.7 h	β+ (17.8%)	653		PET
^124I	4.17 d	β+ (25%)	2138, 1534		PET
^111In	2.8 d	γ (90.6%), γ (94.1%)	171, 245		SPECT
	6.0 h	γ (89%)	140.5		SPECT
^211At	7.2 d	α (42%), γ (21%)	5868	0.8 mm	SPECT, radionuclide therapy
^177Lu	6.7 d	− (78.6%), γ (11%), γ (6%)	498, 208, 113	1.6 mm	SPECT, radionuclide therapy
^131I	8.0 d	β− (89.9%), γ (81.7%)	606, 364	4 mm	SPECT, radionuclide therapy
^225Ac	9.9 d	α (50.7%)	5830	0.9 mm	Radionuclide therapy
^90Y	2.7 d	β− (99.9%)	2280	11 mm	Radionuclide therapy
^89Sr	50.5 d	β− (100%)	1491	7 mm	Radionuclide therapy
^153Sm	1.9 d	β− (44%), β− (34%)	702, 632	3.3 mm	Radionuclide therapy